After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.
Insights: Transfer pricing is not just an international issue
In this issue of Insights, we discuss how states are seeking additional ways to collect revenue, including transfer pricing audits. This is particularly...